Home Cart Sign in  
Chemical Structure| 312636-16-1 Chemical Structure| 312636-16-1

Structure of SKI II
CAS No.: 312636-16-1

Chemical Structure| 312636-16-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SKI II is an inhibitor of non ATP-competitive sphingosine kinase (SphK) with IC50 of 0.5 μM.

Synonyms: Sphingosine Kinase Inhibitor 2; SphK-I2; SKI II. Sphingosine kinase inhibitor II

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SKI II

CAS No. :312636-16-1
Formula : C15H11ClN2OS
M.W : 302.78
SMILES Code : OC1=CC=C(NC2=NC(C3=CC=C(Cl)C=C3)=CS2)C=C1
Synonyms :
Sphingosine Kinase Inhibitor 2; SphK-I2; SKI II. Sphingosine kinase inhibitor II
MDL No. :MFCD00733553
InChI Key :ZFGXZJKLOFCECI-UHFFFAOYSA-N
Pubchem ID :753704

Safety of SKI II

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
U3054MG cells 2.66 µM 5 days Decreased invasion of glioblastoma cell spheroids BMC Cancer. 2023 Aug 16;23(1):762.
HK-2 cells 5 µM 24 hours Inhibition of SK1 activity completely abolished the protective effect of hiPSC-MSCs-EVs on H/R-injured HK-2 cells Cell Death Dis. 2017 Dec 11;8(12):3200.
HeLa 10 µM 24 hours SKI II treatment significantly increased the levels of dhSM and dhCDH in HeLa cells, indicating inhibition of Des1 activity. J Lipid Res. 2014 Aug;55(8):1711-20.
T98G 10 µM 24 hours SKI II treatment significantly increased the levels of dhSM and dhCDH in T98G cells, indicating inhibition of Des1 activity. J Lipid Res. 2014 Aug;55(8):1711-20.
PC12 cells 10 µM 24 hours To study the effect of SKI II on PC12 cell viability, results showed that SKI II significantly decreased the viability of PC12 cells. Neurochem Res. 2014 Apr;39(4):645-52.
CaOV3 ovarian cancer cells 5 µM 24-48 hours SKI-II significantly enhanced curcumin-induced apoptosis and growth inhibition by facilitating ceramide production, p38 activation and Akt inhibition Cancer Sci. 2012 Aug;103(8):1538-45.
HGC 27 10 µM 4 hours SKI II significantly reduced the production of CerC6NBD in HGC 27 cells, indicating inhibition of Des1 activity. J Lipid Res. 2014 Aug;55(8):1711-20.
1080 GSCs 2.66 µM 4 weeks Impaired the self-renewal capacity of temozolomide-resistant GSCs BMC Cancer. 2023 Aug 16;23(1):762.
Rat islet cells 10 or 20 µM 48 hours To assess the effect of SKI II on oleate-induced β-cell proliferation, results showed that SKI II inhibited oleate-induced β-cell proliferation. Diabetes. 2022 Jun 1;71(6):1218-1232.
A2780 ovarian cancer cells 5 µM 48 hours SKI-II synergized with curcumin to inhibit A2780 cell proliferation Cancer Sci. 2012 Aug;103(8):1538-45.
SKOV3 ovarian cancer cells 5 µM 48 hours SKI-II synergized with curcumin to inhibit SKOV3 cell proliferation Cancer Sci. 2012 Aug;103(8):1538-45.
NCH82 cells 2.66 µM 5 days Synergistically inhibited glioblastoma cell growth and potentiated glioblastoma cell death BMC Cancer. 2023 Aug 16;23(1):762.
Primary human peripheral blood lymphocytes (PBL) 5 µM 6-24 hours Reduced phosphorylation of rpS6 and eIF4E, affecting cellular translational capacity Front Physiol. 2022 Mar 17;13:856143.
HT-29 cells 5 µM 72 hours Facilitated ABC294640-induced cytotoxicity against HT-29 cells J Exp Clin Cancer Res. 2015 Sep 4;34(1):94.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice AOM-induced colon carcinogenesis model Oral 100 mg/kg Once a week for 3 weeks SKI-II significantly reduced the number of ACF per colon induced by AOM Carcinogenesis. 2017 Dec 7;38(12):1218-1227
Sprague-Dawley rats Renal ischemia-reperfusion injury model Subcutaneous injection 50 mg/kg Single dose 15 min before reperfusion SK1 inhibition completely abolished the renal protective effect of hiPSC-MSCs-EVs in a rat I/R injury model Cell Death Dis. 2017 Dec 11;8(12):3200.
Wistar rats Glucose and lipid emulsion (GLU + CLI) infusion model Oral gavage 50 mg/kg Once daily for 72 hours To assess the effect of SKI II on GLU + CLI-induced β-cell proliferation, results showed a negative correlation between plasma SKI II levels and β-cell proliferation. Diabetes. 2022 Jun 1;71(6):1218-1232.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.30mL

0.66mL

0.33mL

16.51mL

3.30mL

1.65mL

33.03mL

6.61mL

3.30mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories